Editorial orientation provided by MedAPI — not part of the coding instruction.
C22 covers malignant neoplasms arising in the liver or intrahepatic bile ducts. Major entities include hepatocellular carcinoma, intrahepatic cholangiocarcinoma, hepatoblastoma, hepatic angiosarcoma, and other rare primary hepatic carcinomas or sarcomas.
Common Histologies
- Hepatocellular carcinoma (HCC): The most common primary liver malignancy, often associated with cirrhosis, chronic hepatitis B or C, alcohol-related liver disease, or metabolic dysfunction–associated steatotic liver disease.
- Intrahepatic cholangiocarcinoma: Adenocarcinoma arising from bile ducts within the liver.
- Hepatoblastoma: An embryonal liver tumor occurring predominantly in young children.
- Angiosarcoma and other hepatic sarcomas: Rare malignancies arising from vascular or mesenchymal tissues.
- Other specified or unspecified primary hepatic carcinomas: Used when a primary liver cancer is documented but does not fit a more specific listed type.
Common Symptoms
Early disease may be asymptomatic or detected during surveillance. Presentations can include:
- Right upper-quadrant discomfort or abdominal fullness (R10.11)
- Unintentional weight loss, anorexia, or fatigue (R63.4)
- Hepatomegaly or a palpable abdominal mass (R16.0)
- Jaundice or pruritus, particularly with biliary obstruction (L29.81)
- Ascites or worsening hepatic decompensation (R18.8)
- Fever or abdominal pain from tumor necrosis (R50.81)
- In children (Z76.2), abdominal enlargement (R19.07), or a palpable mass (R22.9)
Diagnosis
Evaluation commonly includes multiphasic contrast-enhanced CT or MRI of the liver, assessment for extrahepatic disease, liver function testing, and tumor markers. In appropriate high-risk patients, HCC may be diagnosed by characteristic arterial enhancement and portal or delayed washout without biopsy. Biopsy is often required when imaging is indeterminate or when cholangiocarcinoma, sarcoma, metastasis, or another histology is suspected.
Relevant markers include:
- Alpha-fetoprotein (AFP): May be elevated in HCC and is frequently elevated in hepatoblastoma, but is not diagnostic by itself.
- CA 19-9 and CEA: May support evaluation of intrahepatic cholangiocarcinoma but lack sufficient specificity for diagnosis alone.
Pathology should establish tumor lineage and distinguish a primary hepatic malignancy from metastatic disease.
Staging
Staging depends on histology:
- HCC: Assessed by tumor number and size, vascular invasion, nodal or distant spread, liver function, portal hypertension, and performance status. Systems such as AJCC TNM and Barcelona Clinic Liver Cancer staging may be used for different clinical purposes.
- Intrahepatic cholangiocarcinoma: Staged separately using tumor extent, multiplicity, vascular involvement, nodal disease, and distant metastasis.
- Hepatoblastoma: Commonly risk-stratified using pediatric systems incorporating PRETEXT imaging groups, vascular involvement, metastatic disease, and AFP.
- Hepatic sarcomas: Staging and risk assessment vary by histologic subtype.
Molecular Markers
Molecular testing is particularly relevant in unresectable or advanced intrahepatic cholangiocarcinoma, where potentially actionable alterations may include FGFR2 fusions or rearrangements, IDH1 variants, BRAF V600E, HER2 alterations, NTRK fusions, RET fusions, microsatellite instability, mismatch-repair deficiency, and high tumor mutational burden.
HCC is generally managed according to clinical stage and liver function; broad molecular profiling may be considered in advanced disease, although routinely actionable drivers are less common than in intrahepatic cholangiocarcinoma.
Common Treatments
Treatment is determined by histology, anatomic extent, hepatic reserve, comorbidities, and transplant eligibility.
- Surgical resection: Potentially curative for selected localized HCC, intrahepatic cholangiocarcinoma, hepatoblastoma, and rare sarcomas.
- Liver transplantation: An option for selected patients with HCC or hepatoblastoma; its role in intrahepatic cholangiocarcinoma is limited to highly selected protocols.
- Locoregional therapy: Ablation, transarterial embolization or chemoembolization, radioembolization, and selected forms of external-beam radiation may be used for HCC and, in selected settings, other hepatic tumors.
- Systemic therapy for HCC: May include immune checkpoint inhibitor–based combinations, antiangiogenic agents, and multikinase inhibitors.
- Systemic therapy for intrahepatic cholangiocarcinoma: Commonly includes gemcitabine- and platinum-based therapy, often with immunotherapy, followed when appropriate by biomarker-directed treatment.
- Hepatoblastoma: Usually treated with pediatric multiagent chemotherapy and complete surgical resection or transplantation.
- Hepatic sarcomas: Managed according to subtype, often with surgery and selected systemic therapy or radiation.
Scope Note
C22 encodes the site and, for some child codes, the documented primary tumor type involving the liver or intrahepatic bile ducts. It does not by itself encode tumor stage, grade, molecular profile, liver function, treatment status, or underlying liver disease. Known secondary malignant neoplasm of the liver or intrahepatic bile ducts is classified separately under C78.7, not C22. Malignancy of the biliary tract without a more specific site is also outside this family. C22.9 indicates that the record does not specify whether the liver malignancy is primary or secondary; it should not be interpreted as confirmation of a primary hepatic cancer. Associated conditions such as chronic hepatitis or alcohol-related disorders may require separate codes when documented.